Teva provides 2013 guidances below Street

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced 2013 revenue and EPS guidances below the Street's estimates on a conference call to discuss its 2013 financial outlook on Friday. President and CEO Jeremy Levin said the company expects 2013 non-GAAP diluted EPS of $4.85-$5.15, coming in below the Street's estimate of $5.65. Teva expects 2013 net revenues of $19.5-$20.5 billion, also below the Street's $20.8 billion estimate. The company also reiterated that it expects 2012 revenue of $20-$21 billion and non-GAAP EPS of $5.30-$5.40. ...